Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2021-08-23
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well brentuximab vedotin and nivolumab work in treating
patients with stage I-II classic Hodgkin lymphoma. Brentuximab vedotin is a monoclonal
antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30
positive cancer cells in a targeted way and delivers vedotin to kill them. Immunotherapy with
monoclonal antibodies, such as nivolumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread.